Hoechst long-term diltiazem use trial planned; CCB labeling should warn of mortality risk -- HRG petition.
DILTIAZEM LARGE-SCALE TRIAL TO ADDRESS CCB CONCERNS about an association between calcium channel blocker use and increased risk of cardiovascular events. In a lead-up announcement to the American Heart Association annual meeting Nov. 13-16 in Anaheim. Hoechst Marion Roussel states that it will conduct a three-year prospective study of Cardizem CD, with the intention of finding "definitive answers about the long-term effects of Cardizem CD in treating high blood pressure."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth